tmem161b Antibody

What is TMEM161B and why is it important in research?

TMEM161B (Transmembrane protein 161B) is a membrane-localized protein with a canonical length of 487 amino acid residues and a mass of 55.5 kDa in humans . It belongs to the TMEM161 protein family and has been identified as crucial for maintaining normal cardiac rhythm during development and for neonatal survival .

Research significance stems from its emerging roles in multiple physiological systems:

• Essential regulator of cardiac rhythm in zebrafish and mice models

• Critical inhibitor of calcium (Ca²⁺) and potassium (K⁺) currents in cardiomyocytes

• Recent implications in structural brain development based on human mutation studies

• Potential role in cancer biology through long non-coding RNA TMEM161B-AS1 interaction

Understanding TMEM161B function requires reliable antibody detection methods, making antibody validation and appropriate application critical for advancing research in these areas.

What are the common applications for TMEM161B antibodies in basic research?

TMEM161B antibodies are primarily utilized for protein detection across several standard laboratory techniques:

• Western Blot (WB): Most widely used application for detecting TMEM161B expression levels and confirming protein size. Particularly useful when comparing expression between experimental conditions or different tissue samples .

• Enzyme-Linked Immunosorbent Assay (ELISA): Common application for quantitative measurement of TMEM161B in tissue or cell lysates, allowing for sensitive detection of protein concentration differences .

• Immunocytochemistry/Immunofluorescence (ICC-IF): Used to visualize TMEM161B subcellular localization, particularly its reported membrane distribution. This application has confirmed TMEM161B localization at cardiomyocyte plasma membranes .

• Immunohistochemistry (IHC): Applied to tissue sections to examine TMEM161B distribution across different cell types within a tissue context .

For optimal results, researchers should select antibodies specifically validated for their intended application and species of interest, as reactivity can vary significantly between antibodies from different suppliers.

How can I validate a TMEM161B antibody for my specific experimental system?

Thorough validation of TMEM161B antibodies is essential for generating reliable research data. A comprehensive validation approach includes:

• Positive and negative controls:

  • Positive: Use tissue with confirmed TMEM161B expression (heart tissue is ideal based on known expression patterns)

  • Negative: Include TMEM161B knockout samples or tissues known to lack expression

  • siRNA/shRNA knockdown: Perform partial knockdown to demonstrate signal reduction correlating with reduced protein levels

• Signal specificity assessment:

  • Verify the molecular weight matches the expected 55.5 kDa in Western blots (accounting for potential post-translational modifications like glycosylation)

  • Confirm subcellular localization pattern is consistent with membrane distribution

  • Test multiple antibodies targeting different epitopes when possible

• Cross-reactivity testing:

  • If working with non-human species, confirm antibody reactivity with the orthologous protein

  • Antibody data sheets often list confirmed reactivity (human, mouse, rat, etc.)

• Application-specific validation:

  • For ICC/IF: Include membrane co-localization markers

  • For IHC: Compare staining patterns with mRNA expression data from public databases

  • For WB: Include positive control lysates from tissues known to express TMEM161B

Document all validation steps thoroughly to support the reliability of subsequent experimental findings.

How do I investigate TMEM161B's role in calcium and potassium channel regulation in cardiomyocytes?

Investigating TMEM161B's regulatory effect on calcium and potassium channels requires specialized electrophysiological approaches combined with immunological techniques:

Experimental Design Strategy:

• Patch-clamp electrophysiology with TMEM161B manipulation:

  • Compare action potential characteristics between wild-type and TMEM161B-deficient cardiomyocytes

  • Measure specific ion currents (IKr and ICaL) while controlling for other variables

  • Use selective channel blockers to isolate TMEM161B-dependent currents

• Calcium imaging approaches:

  • Implement gCaMP reporters to quantify calcium transient amplitude and kinetics

  • Compare oscillation patterns between wild-type and TMEM161B-deficient cells

  • Time-lapse imaging to capture arrhythmic calcium oscillations reported in knockout models

• Co-immunoprecipitation studies:

  • Use TMEM161B antibodies to pull down potential channel interacting partners

  • Probe for calcium and potassium channel subunits to identify direct interactions

  • Confirm interactions through reverse co-IP and proximity ligation assays

• Channel expression and localization analysis:

  • Quantify channel subunit expression levels in presence/absence of TMEM161B

  • Assess membrane trafficking of channels using subcellular fractionation and TMEM161B antibodies

  • Examine co-localization patterns of TMEM161B with channel components

These approaches can be supplemented with in vivo cardiac phenotyping using ECG recordings to correlate cellular findings with whole-organ physiology, as demonstrated in zebrafish and mouse models .

What are the best practices for using TMEM161B antibodies in cross-species research?

Cross-species research with TMEM161B antibodies requires careful consideration of evolutionary conservation and epitope specificity:

Methodological Considerations:

• Sequence homology assessment:

  • TMEM161B shows conservation across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken

  • Perform sequence alignment of target epitopes between species to predict cross-reactivity

  • Select antibodies recognizing highly conserved regions for multi-species applications

• Epitope-specific validation:

  • Test antibodies against recombinant proteins from each species of interest

  • Validate with positive controls from each species alongside negative controls

  • Consider species-specific post-translational modifications that might affect epitope accessibility

• Application optimization across species:

  • Adjust protocols based on species-specific tissues (fixation times, antigen retrieval methods)

  • Optimize antibody concentration individually for each species

  • Document differential detection sensitivity between species

• Confirmation strategies:

  • Implement parallel approaches (e.g., mRNA detection) to confirm protein expression patterns

  • Use CRISPR-edited cells/tissues as definitive controls for antibody specificity

  • When possible, compare multiple antibodies targeting different epitopes

• Cross-species reactivity table:

This approach ensures reliable interpretation of cross-species data while minimizing false positives or negatives from antibody specificity variations.

How can I investigate the relationship between TMEM161B and its antisense transcript TMEM161B-AS1 in glioblastoma research?

Investigating the functional relationship between TMEM161B protein and the long non-coding RNA TMEM161B-AS1 in glioblastoma requires integrated approaches:

Research Strategy:

• Expression correlation analysis:

  • Quantify both TMEM161B protein (using validated antibodies) and TMEM161B-AS1 RNA across glioblastoma cell lines and patient samples

  • Determine whether TMEM161B-AS1 knockdown affects TMEM161B protein levels through Western blotting

  • Assess whether TMEM161B overexpression affects TMEM161B-AS1 expression

• Functional interaction studies:

  • Implement RNA immunoprecipitation using TMEM161B antibodies to detect direct RNA-protein interactions

  • Perform subcellular co-localization studies to determine if TMEM161B and TMEM161B-AS1 share cellular compartments

  • Use CRISPR-based approaches to modulate each component independently and assess impact on the other

• Pathway analysis:

  • Based on findings that TMEM161B-AS1 affects FANCD2 and CD44 expression by sponging hsa-miR-27a-3p , investigate whether TMEM161B protein functions within this same pathway

  • Examine TMEM161B protein expression in relation to miR-27a-3p levels

  • Assess downstream effects on temozolomide resistance when modulating TMEM161B versus TMEM161B-AS1

• Clinical correlation:

  • Compare TMEM161B protein expression (via immunohistochemistry) with TMEM161B-AS1 expression in patient samples

  • Correlate expression patterns with patient outcomes and treatment response

  • Develop a prediction model incorporating both markers for potential clinical application

This integrated approach can help determine whether TMEM161B and TMEM161B-AS1 function through independent or interconnected mechanisms in glioblastoma pathophysiology, potentially revealing new therapeutic targets .

What technical challenges may arise when working with TMEM161B antibodies and how can they be addressed?

Researchers working with TMEM161B antibodies commonly encounter several technical challenges that require specific troubleshooting approaches:

Common Issues and Solutions:

• Non-specific binding and background signal:

  • Problem: Multiple bands in Western blots or diffuse staining in immunofluorescence

  • Solutions:

    • Implement more stringent blocking protocols (5% BSA instead of milk for transmembrane proteins)

    • Optimize antibody concentration through titration experiments

    • Include additional washing steps with increased detergent concentration

    • Use knockout/knockdown controls to identify specific versus non-specific signals

• Detection of multiple isoforms:

  • Problem: Up to 3 different isoforms have been reported for TMEM161B , complicating interpretation

  • Solutions:

    • Use isoform-specific antibodies when available

    • Compare observed banding patterns with predicted molecular weights of known isoforms

    • Employ RT-PCR to correlate protein bands with expressed transcript variants

    • Document tissue-specific expression patterns of different isoforms

• Post-translational modifications:

  • Problem: Glycosylation of TMEM161B can alter apparent molecular weight and epitope accessibility

  • Solutions:

    • Treat samples with deglycosylation enzymes before Western blotting to confirm identity

    • Use denaturing conditions that maintain epitope integrity while removing confounding modifications

    • Select antibodies targeting regions less affected by post-translational modifications

• Low abundance detection:

  • Problem: TMEM161B may be expressed at low levels in some tissues

  • Solutions:

    • Implement signal amplification techniques (e.g., TSA for immunohistochemistry)

    • Increase protein loading for Western blots combined with enhanced chemiluminescence

    • Use more sensitive detection methods like multiphoton microscopy for tissue sections

    • Consider enrichment of membrane fractions before analysis

• Fixation artifacts in immunohistochemistry/immunofluorescence:

  • Problem: Membrane proteins can be particularly sensitive to fixation conditions

  • Solutions:

    • Compare multiple fixation protocols (PFA, methanol, acetone) to optimize epitope preservation

    • Implement antigen retrieval methods specifically optimized for membrane proteins

    • Test live-cell antibody staining for surface-exposed epitopes

    • Document optimal fixation parameters for specific antibody clones

These methodological considerations can significantly improve data quality and reproducibility when working with TMEM161B antibodies across different experimental systems.

How can TMEM161B antibodies be utilized in studying its role in cardiac development and arrhythmias?

TMEM161B has been established as an essential regulator of cardiac rhythm and morphology through studies in zebrafish and mouse models . Investigating its role in cardiac development and arrhythmias requires specialized approaches:

Integrated Research Methodology:

• Developmental expression profiling:

  • Use TMEM161B antibodies for temporal expression analysis throughout cardiac development

  • Implement co-immunostaining with cardiac differentiation markers to identify temporal relationships

  • Compare expression patterns between normal and pathological developing hearts

• Functional assessment in cardiomyocytes:

  • Combined immunofluorescence and electrophysiology approaches:

    • Correlate TMEM161B localization with functional membrane properties

    • Implement patch-clamp recordings in regions with differential TMEM161B expression

    • Document changes in action potential characteristics relative to TMEM161B expression levels

• Ion channel interaction studies:

  • Based on findings that TMEM161B inhibits IKr and ICaL currents :

    • Perform co-immunoprecipitation with TMEM161B antibodies followed by mass spectrometry

    • Analyze proximity to specific calcium and potassium channel subunits using FRET-based approaches

    • Assess channel modification (phosphorylation, trafficking) in presence/absence of TMEM161B

• In vivo cardiac phenotyping protocol:

  • Correlate cardiac structural phenotypes with TMEM161B expression:

    • Use echocardiography or microCT to assess cardiac morphology

    • Compare immunohistochemical TMEM161B distribution with functional defects

    • Implement optical mapping to correlate conduction abnormalities with TMEM161B distribution

• Translational approaches:

  • Apply findings from animal models to human samples:

    • Analyze TMEM161B expression in human cardiac tissue samples with arrhythmic conditions

    • Compare expression patterns between normal and pathological human heart samples

    • Correlate genetic variants with protein expression levels and distribution

This integrated approach leverages TMEM161B antibodies for both mechanistic understanding and potential therapeutic development targeting cardiac arrhythmias.

What controls should be included when using TMEM161B antibodies in experiments examining brain malformations?

Recent studies have identified TMEM161B mutations in patients with structural brain malformations including polymicrogyria, seizures, and developmental delays . Properly controlled experiments using TMEM161B antibodies are essential for investigating these phenotypes:

Comprehensive Control Strategy:

• Genetic controls:

  • Wild-type vs. TMEM161B mutant tissues (ideally containing patient-specific mutations)

  • Hypomorphic vs. complete knockout models to distinguish dosage effects

  • Tissue-specific conditional knockouts to isolate neuronal vs. glial contributions

• Developmental stage controls:

  • Age-matched samples across crucial neurodevelopmental timepoints

  • Comparison between embryonic, early postnatal, and mature brain tissues

  • Documentation of TMEM161B expression dynamics throughout cortical development

• Anatomical region controls:

  • Affected vs. unaffected brain regions within the same specimen

  • Comparison between cortical regions with different folding complexity

  • Inclusion of subcortical structures as internal references

• Cellular specificity controls:

  • Co-staining with neural progenitor markers (Sox2, Pax6)

  • Co-staining with neuronal migration markers (Dcx)

  • Comparison between neuronal and glial TMEM161B expression patterns

• Technical validation controls:

  • Secondary-only antibody controls to assess background

  • Peptide competition assays to confirm specificity

  • Comparison of multiple antibodies targeting different TMEM161B epitopes

  • Inclusion of tissues from confirmed TMEM161B knockout models

• Functional correlation controls:

  • Calcium imaging in neural cells with wild-type vs. mutant TMEM161B

  • Electrophysiological assessment of neurons expressing different TMEM161B variants

  • Correlation of protein expression with severity of structural malformations

This systematic approach ensures that findings related to TMEM161B's role in brain development are robust and reproducible, potentially illuminating mechanisms underlying the observed clinical phenotypes in affected individuals .

What are the emerging research directions for TMEM161B antibodies in translational medicine?

TMEM161B research is rapidly evolving with significant translational potential in multiple disease contexts. TMEM161B antibodies will play crucial roles in advancing several promising research directions:

• Cardiac arrhythmia therapeutic development:

  • TMEM161B's established role in cardiac rhythm regulation presents opportunities for targeted interventions

  • Antibodies enable screening of compounds that modulate TMEM161B function or expression

  • Monitoring TMEM161B expression changes in response to anti-arrhythmic treatments

• Neurodevelopmental disorder diagnostics:

  • The association between TMEM161B mutations and brain malformations suggests diagnostic applications

  • Antibodies can help characterize TMEM161B expression patterns in accessible patient samples

  • Development of immunoassays for early detection of TMEM161B-related pathologies

• Cancer biology and therapeutic resistance:

  • Emerging relationships between TMEM161B-AS1 and glioblastoma suggests potential roles in cancer

  • Antibodies facilitate investigation of TMEM161B protein in the context of temozolomide resistance

  • Combined targeting of TMEM161B and its regulatory RNAs may offer novel therapeutic approaches

• Ion channel modulation:

  • TMEM161B's role in regulating calcium and potassium currents presents opportunities

  • Antibodies enable screening of compounds that affect TMEM161B-channel interactions

  • Development of specific modulators of TMEM161B activity could address channelopathies

• Cross-system disease connections:

  • TMEM161B's involvement in both cardiac and neurological phenotypes suggests common mechanisms

  • Antibodies allow investigation of shared pathways across multiple organ systems

  • Understanding tissue-specific regulatory mechanisms may reveal specialized therapeutic approaches